Odyssey Therapeutics, Inc Common Stock
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $959 | $1,918 |
EBITDA | -51,733 | -37,018 | ||
EBIT | -52,776 | -38,189 | ||
Net Income | -52,788 | -38,262 | -41,235 | -38,435 |
Net Change In Cash | 0 | 0 | 959 | 1,918 |
Free Cash Flow | -34,694 | -41,183 | -34,290 | -39,548 |
Cash | 82,031 | 35,719 | ||
Basic Shares | 30,277 | 47,174 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $2,976 | $4,472 | $1,037 | $0 |
Gross Profit | 2,976 | |||
EBITDA | -144,646 | |||
EBIT | -149,557 | |||
Net Income | -148,647 | -129,321 | -125,938 | -124,665 |
Net Change In Cash | 2,976 | 4,472 | 1,037 | 0 |
Free Cash Flow | -130,700 | -118,235 | -117,784 | -112,869 |
Cash | 41,687 | 59,136 | 52,545 | 241,043 |
Basic Shares | 27,561 | 47,174 | 47,174 | 47,174 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$1.26 |
2026-03-31 | -$6.74 |